 |
인쇄하기
취소
|
Green Cross to develope anti-cancer genetic therapy.
Green Cross has agreed with an exclusive distribution of JX-594, an anti-cancer genetic therapy by the use of recombinant vaccinia virus, with American Generics Biotherapeutics Inc.
JX-594 is a new type of an anti-cancer therapy by combining the GM-CSF granulocyte macrophage colony stimulating factor by enhancing the immunity of the selective oncolytic virus to kill tumor cells only without ...
JX-594 is a new type of an anti-cancer therapy by combining the GM-CSF granulocyte macrophage colony stimulating factor by enhancing the immunity of the selective oncolytic virus to kill tumor cells only without ...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.